In patients with resistant hypertension, renal denervation plus standardized stepped-care antihypertensive treatment (SSAHT) resulted in significant blood-pressure lowering compared with SSAHT alone. These new data from the DENERHTN trial may indicate that despite the failure of SYMPLICITY HTN-3, there is light at the end of the tunnel for renal denervation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Azizi, M. et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 26, http://dx.doi.org/10.1016/S0140-6736(14)61942-5.
Bhatt, D. L. et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 370, 1393–1401 (2014).
Symplicity HTN-2 Investigators et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376, 1903–1909 (2010).
Fadl Elmula, F. E. M. et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 63, 691–699 (2014).
Rosa, J. et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension 65, 407–413 (2014).
Staessen, J. A. et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office. A randomized controlled trial. JAMA 291, 955–964 (2004).
Colloca, L. & Finniss, D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA 307, 567–568 (2012).
Kjeldsen, S. E., Flaaten, B., Eide, I., Helgeland, A. & Leren, P. Increased peripheral release of noradrenaline and uptake of adrenaline in essential hypertension? Clin. Sci. (Lond.) 61 (Suppl. 7), 215s–217s (1981).
Gal, P. et al. Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study. J. Hum. Hypertens. http://dx.doi.org/10.1038/jhh.2014.91.
Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension. Durability of blood pressure reduction out to 24 months. Hypertension 57, 911–917 (2011).
Acknowledgements
The authors are grateful to the investigators of the European Network Coordinating Research on Renal Denervation, who substantially contributed to the insights expressed in this commentary. They are especially indebted to Y. Jin (University of Leuven, Belgium), F. E. M. Fadl Elmula and S. E. Kjeldsen (both University of Oslo, Norway).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Yang, WY., Staessen, J. Renal denervation—promising data from the DENERHTN trial. Nat Rev Nephrol 11, 258–260 (2015). https://doi.org/10.1038/nrneph.2015.28
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2015.28
